What do the works of Dutch graphic artist MC Escher and plenum retrofits for existing blown film lines have in common? They make the impossible possible. That's just what equipment manufacturer for ...
After mulling over the data from a failed phase 2 trial, Johnson & Johnson has decided to halt development of its Addex Therapeutics-partnered epilepsy drug, Fierce Biotech has learned. The positive ...
Addex Therapeutics’ attempt to expand use of dipraglurant into muscle spasms has stumbled at the first hurdle. A phase 2a clinical trial of the mGluR5 negative allosteric modulator has delivered ...
Geneva, Switzerland and New York, USA, April 3, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development, ...
Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique ...
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Addex Therapeutics ( (CH:ADXN)) has ...
ZURICH (Reuters) - Shares in Addex jumped on Tuesday after the Swiss biotech said it could get up to 112 million euros in a deal with Johnson & Johnson unit Ortho-McNeil-Janssen Pharmaceuticals Inc.
Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique ...
Geneva, Switzerland, November 11, 2024-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results